VIDEO: Bimekizumab a 'major advantage' for skin clearance in psoriasis
Click Here to Manage Email Alerts
In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, discussed results from a recent study evaluating bimekizumab in patients with plaque psoriasis.
The study, BE RADIANT, was among the late-breaking research presented at AAD VMX 2021.
Gelfand said that more patients who received bimekizumab achieved Psoriasis Area and Severity Index 100 at 16 weeks and skin clearance at 48 weeks compared with those who received Cosentyx (secukinumab, Novartis).
“This is a major advantage in our treatment of psoriasis, in terms of the ability to clear people at such a high rate,” Gelfand said.
However, he noted that patients in the bimekizumab group were more likely to develop fungal infection than those in the secukinumab group.
Due to this finding, Gelfand said that “clinicians and patients will need to decide if the extra benefit you receive from clearing your psoriasis [is] worth the risk for mild nuisance skin infections,” noting that the infections observed among patients included in the study were typically not serious enough to lead to discontinuation.
Collapse
Click Here to Manage Email Alerts